Education
About Us
Working with TipRanks
Follow Us
Pmv Pharmaceuticals, Inc. (PMVP)
NASDAQ:PMVP
PMVP Stock Chart & Stats
$1.12
-$0.01(-0.65%)
At close: 4:00 PM EST
$1.12
-$0.01(-0.65%)
Day’s Range― - ―
52-Week Range$0.81 - $1.88
Previous CloseN/A
Volume81.53K
Average Volume (3M)778.03K
Market Cap
$86.20M
Enterprise Value$44.41M
Total Cash (Recent Filing)$129.25M
Total Debt (Recent Filing)$931.00K
Price to Earnings (P/E)―
Beta0.43
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,211,506
10 Day Avg. Volume1,752,957
30 Day Avg. Volume778,033
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.50
Enterprise Value/Market Cap0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-693.93
Enterprise Value/Ebitda-0.50
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Strategic InterestA cash balance sufficient to fund operations into 2027, coupled with noted interest from potential buyers, reduces near-term financing pressure and increases takeover appeal.
Clinical EfficacyPYNNACLE trial results showing a 46% overall response rate and durable responses support the drug's potential to meet efficacy expectations for regulators and acquirers.
Safety ProfileA low treatment discontinuation rate of 4% for drug-related adverse events indicates a manageable safety profile that could ease regulatory review and commercial adoption.
Bears Say
Development Timeline RiskNegative clinical data or delays in advancing candidates into later-stage trials could push back commercialization timelines and depress the stock.
Dilution And Commercial ExecutionNeed for additional capital or lower-than-expected commercial uptake could lead to share dilution and weaker revenue delivery per share.
Regulatory Approval RiskFailure to obtain regulatory approval for the lead candidate would sharply reduce projected revenues and investor confidence.
PMV Pharmaceuticals News
PMVP FAQ
What was Pmv Pharmaceuticals, Inc.’s price range in the past 12 months?
Pmv Pharmaceuticals, Inc. lowest stock price was $0.81 and its highest was $1.88 in the past 12 months.
What is Pmv Pharmaceuticals, Inc.’s market cap?
Pmv Pharmaceuticals, Inc.’s market cap is $86.20M.
When is Pmv Pharmaceuticals, Inc.’s upcoming earnings report date?
Pmv Pharmaceuticals, Inc.’s upcoming earnings report date is May 08, 2026 which is in 64 days.
How were Pmv Pharmaceuticals, Inc.’s earnings last quarter?
Currently, no data Available
Is Pmv Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Pmv Pharmaceuticals, Inc.’s price is currently Overvalued.
Does Pmv Pharmaceuticals, Inc. pay dividends?
Pmv Pharmaceuticals, Inc. does not currently pay dividends.
What is Pmv Pharmaceuticals, Inc.’s EPS estimate?
Pmv Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pmv Pharmaceuticals, Inc. have?
Pmv Pharmaceuticals, Inc. has 53,211,506 shares outstanding.
What happened to Pmv Pharmaceuticals, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pmv Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in PMVP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PMV Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
PMVP Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.72%
12-Months-Change
Fundamentals
Return on Equity
-51.87%
Trailing 12-Months
Asset Growth
-40.11%
Trailing 12-Months
Company Description
Pmv Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Prelude Therapeutics
―
Gain Therapeutics
―
Immix Biopharma
―
Ownership Overview
12.71% Insiders
8.60% Mutual Funds
14.72% Other Institutional Investors
60.17% Public Companies and
Individual Investors